First chikungunya vaccine approved
European Pharmaceutical Review
NOVEMBER 10, 2023
The vaccine was granted PRIority MEdicine (PRIME) designation by the EMA in 2020. As part of the US FDA approval, the FDA stated that the company is required to conduct a postmarketing study to assess the serious risk of severe chikungunya-like adverse reactions following administration of IXCHIQ.
Let's personalize your content